Video

Dr. Luke on the FDA Approval of Adjuvant Nivolumab in Melanoma

Author(s):

Jason J. Luke, MD

In Partnership With:

Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the FDA approval of nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.

Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the FDA approval of nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.

Related Videos
Lori Wirth, MD
Tanios Bekaii-Saab, MD, FACP
Moritz Fürstenau, MD
Jun Gong, MD
Thierry Facon, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Marshall Posner, MD
Renee Saliby, MD, MSc
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Related Content
The FDA has received a biologics license application resubmission for cosibelimab in locally advanced or metastatic cutaneous squamous cell carcinoma.
Published: July 25th 2024 | Updated: July 25th 2024

FDA Accepts Resubmission of BLA for Cosibelimab in Locally Advanced or Metastatic CSCC

Ari Rosenberg, MD, assistant professor, medicine, University of Chicago Medicine
June 17th 2024

Rosenberg Reviews the Evolving Role of Toripalimab in Nasopharyngeal Carcinoma

Suthee Rapisuwon, MD
July 16th 2024

Adjuvant Nivolumab/Ipilimumab Lengthens DMFS in High-Risk Uveal Melanoma

Ryan Merkow, MD, MS, associate professor, surgery, director, Surgical Cancer Quality, associate director, Health Services Research, Department of Surgery, director, Hepatic Artery Infusion Pump Program, University of Chicago Medicine Comprehensive Cancer Center and Cancer Service Line; Louise Catherine Connell, MB BCh BAO, BMedSc, assistant attending physician, Memorial Sloan Kettering Cancer Center
May 2nd 2024

Merkow and Connell Highlight Considerations for HAI Pump Use in CRC

Robert Metcalf, MBChB, MRCP, PhD, of Christie National Health Service Foundation Trust
July 11th 2024

First-line Eftilagimod Alpha Plus Pembrolizumab Generates Favorable ORR in PD-L1–Negative HNSCC

Don Dizon, MD, of Lifespan Cancer Institute
July 10th 2024

Nivolumab/Ipilimumab Yields Responses in Ovarian Clear Cell Carcinoma